IJCRR - vol 08 issue 08, April, 2016
BIOAVAILABILITY AND BIOEQUIVALENCE EVALUATION OF SOME GENERIC PRODUCTS OF ARTEMETHER-LUMEFANTRINE DOUBLE STRENGTH TABLETS MARKETED IN NIGERIA
Author: Awofisayo Sunday O., Okhamafe Augustine O., Arhewoh Matthew I.
The study was aimed at evaluating the bioavailability and bioequivalence of generic products of artemether-lumefantrine (AL) antimalarial double strength oral tablet formulation. A non-randomized open label single dose study in eighteen healthy African male subjects was designed. The volunteers were administered one tablet of a product with a fatty meal and 0.5 L of water, after overnight fast. Venous blood sampling was taken at 0, 1, 2, 4, 6 and 8 h post-dose and plasma samples analyzed for artemether and lumefantrine exposure simultaneously using a validated high performance liquid chromatographic system with Chromosil C18 column, flow rate and UV detection at 1.0 mL/min and 216 nm, respectively. Acetonitrile: potassium dihydrogen phosphate (70: 30%, v/v) and nevirapine were employed as mobile phase and internal standard, respectively. The primary endpoints were area under the plasma concentration time curve (AUC) from zero to 8 h and maximum plasma concentration (Cmax). The 90% confidence interval for the ratio of the geometric means of AUC0-8 was compared with the established bioequivalence limit. All enrolled subjects with mean age 28.5 ± 4.5 years completed the study. The Cmax for artemether and lumefantrine for the products ranged from 0.225 - 0.558 µg/mL and 0.319 – 0.517 µg/mL, respectively. Drug products AL1 and AL2 met the bioequivalence criteria. The other products failed the pharmacopoeia test specification for chemical content with respect to either or both API and their pharmacokinetic profiles varied with statistical significant differences (P>0.05). Only two of the generic products studied were bioequivalent and could be switched.
Keywords: Bioavailability, Bioequivalence, Pharmacokinetics, Artemether, Lumefantrine
Awofisayo Sunday O., Okhamafe Augustine O., Arhewoh Matthew I.. BIOAVAILABILITY AND BIOEQUIVALENCE EVALUATION OF SOME GENERIC PRODUCTS OF ARTEMETHER-LUMEFANTRINE DOUBLE STRENGTH TABLETS MARKETED IN NIGERIA International Journal of Current Research and Review. vol 08 issue 08, April, 08-14
1. Abdou H.M. 1989. Dissolution, bioavailability and Bioequivalence. Easton: MACK Publishing Company.
2. Cesar I.C., Nogueira F.H.A. and Pianetti G.A. 2008. Simultaneous determination of artemether-lumefantrine in fixed dose combination tablets by HPLC with UV detection. J Pharm and Biomed Anal 48: 951-954.
3. Chow S.C., Liu J.P. 1992. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel and Dekker, Inc.
4. Committee for Proprietary Medicinal Products. 1992. Notes for Guidance Investigation of Bioavailability and Bioequivalence (III/54/89/EN), CPMP, Brussels.
5. Dondorp A., Nosten F., Stepniewska K., Day N. and White N. 2005. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomized trial. Lancet. 366:717- 725.
6. FDA US Food and Drug Administration, CDER (Center for Drug Evaluation and Research). 2002. Guidance for Industry: Food Effect bioavailability and fed bioequivalence studies.
7. Federal Republic of Nigeria. 2005. National Antimalarial Treatment Policy. Federal Ministry of Health, National Malaria and Vector Control Division, Abuja, Nigeria, Pp 1-35.
8. Guidelines on the design of a single-dose in-vivo bioavailability study, Bioavailability and Bioequivalence Requirements, 21 CFR. 1991. 320:26.
9. Henderson J.D., Dighe S.V., Williams P.L. 1992. Subject selection and management in bioequivalence studies. Clinical Research and Regulatory Affairs 9: 71-87.
10. Huang L., Li X., Marzan F., Lizak P.S., Aweeka T.A. 2012. Determination of lumefantrine in small-volume human plasma by LC-MS/MS using deuteriated lumefantrine to overcome matrix effect and ionization saturation. Bio-analysis 4: 157-166.
11. International Conference on Harmonization. 1995. Structure and Content of Clinical Study Report; E3.
12. Kaur H., Goodman C., Thompson E., Thompson K.A., Masanya I. et al. 2008. A nationwide Survey of the Quality of Antimalarials in Retail Outlets in Tanzania. PLoS ONE 3: 1-7.
13. Martinez M.N. and Amidon G.L. 2001. A Mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42: 620 – 43.
14. Minzi O.M.S., Maraelle I.A., Shekalaghe S., Juma O., Ngaimisi E. et al. 2013. Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product. Mal J 12: 174-186.
15. Nayyar G., Bremen J.G., Newton P.N. and Herrington J. 2012. Poor-quality antimalarial drugs in Southeast Asia and Sub-Saharan Africa. Lancet Infect Dis. 12: 488-496.
16. Pabst G., Jaeger H. 1990. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Cancer 38:5-8.
17. Ribeiro W., Zappi E.A., Moraes M.E., Bezerra F.A., Lerner F.E. et al., 2000. Comparative bioavailability of two fluconazole capsule formulations in healthy volunteers. Arzneimittelforschung 50:1028-1032.
18. Sethi P., Dua V.K., Jain R. 2011. A LC-MS/MS method for the determination of lumefantrine and its metabolite desbutyl lumefantrine in plasma from patients infected with Plasmodium falciparum malaria. J Liq Chromatr and Related Tech 34:25-35.
19. Souppart C., Gauducheau N., Samdrenam N., Richard F. 2002. Development and validation of a high performance liquid chromatography- mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J Chromatography B 774: 195-203.
20. USP XXII/NFXVII. 1990. United States Pharmacopoeia Convention, Inc., Rockville, Maryland. Pp1578-1579.
21. USP. 2001 In-vitro and In-vivo evaluation of dosage forms . In United States Pharmacopeias and National formulary USP 26 – NF 21. United States Pharmacopeia Convention, Inc.: Rockville, MD.
22. World Health Organization. 2013. World Malaria Report; Geneva, Switzerland; http:// www.WHO. Int/malaria/world_malaria_report_2013/en/ (Accessed on June16, 2014).
23. World Medical Association. 2013. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 3100 (2): 2191-94.